ORSERDU Drug Patent Profile
✉ Email this page to a colleague
When do Orserdu patents expire, and what generic alternatives are available?
Orserdu is a drug marketed by Stemline Therap and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred and five patent family members in twenty-four countries.
The generic ingredient in ORSERDU is elacestrant dihydrochloride. One supplier is listed for this compound. Additional details are available on the elacestrant dihydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Orserdu
Orserdu will be eligible for patent challenges on January 27, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 27, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ORSERDU
| International Patents: | 105 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Patent Applications: | 109 |
| Drug Prices: | Drug price information for ORSERDU |
| What excipients (inactive ingredients) are in ORSERDU? | ORSERDU excipients list |
| DailyMed Link: | ORSERDU at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ORSERDU
Generic Entry Date for ORSERDU*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ORSERDU
| Drug Class | Estrogen Receptor Antagonist |
| Mechanism of Action | Breast Cancer Resistance Protein Inhibitors Estrogen Receptor Antagonists P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ORSERDU
US Patents and Regulatory Information for ORSERDU
ORSERDU is protected by eight US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ORSERDU is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ORSERDU
Method of treating cancer using selective estrogen receptor modulators
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Polymorphic forms of RAD1901-2HCL
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Method of treating cancer using selective estrogen receptor modulators
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Polymorphic forms of RAD1901-2HCl
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER
Selective estrogen receptor modulator
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF AN ER-POSITIVE BREAST CANCER
FDA Regulatory Exclusivity protecting ORSERDU
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
International Patents for ORSERDU
See the table below for patents covering ORSERDU around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2018514593 | 癌を治療するための方法 | ⤷ Try a Trial |
| Israel | 255189 | צירוף של rad1901 ומעכב cdk4/6 לשימוש בטיפול בסרטן (A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer) | ⤷ Try a Trial |
| Israel | 310069 | שיטות לטיפול בסרטן (Methods of treating cancer) | ⤷ Try a Trial |
| South Korea | 20180042155 | 암을 치료하는 방법 | ⤷ Try a Trial |
| Australia | 2016256471 | Methods of treating cancer | ⤷ Try a Trial |
| Japan | 2021102640 | 癌を治療するための方法 (METHODS FOR TREATING CANCER) | ⤷ Try a Trial |
| Israel | 307981 | שיטות לטיפול בסרטן (Methods for treating cancer) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ORSERDU
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3122426 | LUC00331 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
| 3122426 | PA2024504 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANTAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1757 20230915 |
| 3122426 | 2024C/505 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
| 3122426 | 301263 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1757 20230918 |
| 3122426 | CA 2024 00007 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1757 20230918 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
